According to the European Society of Cardiology 2019 guidelines and the European Association for the Study of Diabetes 2019, patients with type 2 diabetes who have ASCVD or high cardiovascular risk should use SGLT-2 inhibitors or GLP-1 receptor agonists [38,43]. This evidence concerns the gene SLC5A2 and atherosclerosis.